Abbott Laboratories is rated Buy with a 12-month price target of $126, seen as a strong entry point after a recent stock decline following its acquisition of Exact Sciences. The acquisition temporarily lowers 2026 earnings per share by $0.20 but adds a promising oncology diagnostics segment, positioning Abbott for sustained growth. Despite trading at a 10-year low valuation of 17.7 times forward earnings, the company maintains solid revenue growth of 7-8% and a 52-year streak of dividend increases. Long-term investors can expect operational leverage, a robust product pipeline, and cost synergies to drive 9-12% earnings growth beyond 2026.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
